Efficacy, safety, and tolerability of IB-MS versus placebo in patients with progressive forms of MS: Preliminary results from a phase II, randomized, placebo-controlled, double blind, proof-ofconcept study

Authors
Category Primary study
JournalMultiple Sclerosis Journal
Year 2019
This article has no abstract
Epistemonikos ID: bc403344f0407f574b737422ca056a5c0c3a9875
First added on: Feb 11, 2025